版本:
中国

BRIEF-Synergy Pharmaceuticals says to present positive TRULANCE phase 3 data

May 9 Synergy Pharmaceuticals Inc:

* To present positive TRULANCE phase 3 data

* TRULANCE 3 mg,6 mg doses met primary endpoint

* TRULANCE 3 mg,6 mg doses showed statistical significance in percent of patients who were overall responders compared to placebo Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐